Krishna Vaddi
12Patents
4h-index
16Co-inventors
53Inventor score
Filing activity: Apr 2, 2004 → Jan 27, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8541425B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Chemistry; Metallurgy | 80 | Active |
| US8933086B2 | Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors | Chemistry; Metallurgy | 66 | Active |
| US8946245B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Chemistry; Metallurgy | 65 | Active |
| US9206187B2 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase | Chemistry; Metallurgy | 50 | Active |
| US10653628B2 | High surface-area lyophilized compositions comprising arsenic for oral administration in patients | Human Necessities | 2 | Active |
| US10111836B2 | High surface-area lyophilized compositions comprising arsenic for oral administration in patients | Human Necessities | 2 | Active |
| US10272045B2 | High surface-area lyophilized compositions comprising arsenic for oral administration in patients | Human Necessities | 1 | Active |
| US8088737B2 | Compositions, methods and kits relating to Her-2 cleavage | Human Necessities | 1 | Active |
| US9345677B2 | Compositions, methods and kits relating to HER-2 cleavage | Human Necessities | 0 | Active |
| US7910108B2 | Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases | Human Necessities | 0 | Active |
| US12364664B2 | Lyophilized compositions comprising arsenic | Human Necessities | 0 | Active |
| US11220524B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.